Sofinnova Biovelocita II has exceeded its target, successfully raising €165 million, with substantial backing from global pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures.  

The milestone marks a significant expansion of Sofinnova Partners’ biotech acceleration strategy, extending beyond Italy to include France, the UK, and Denmark, with ambitions to further reach additional European countries in the future. 

Since its launch, the fund has screened over 300 projects and made several investments into new companies across Europe.  

Among the newly established companies are BioClec, focused on breakthrough therapies for Alzheimer’s disease; Forth Therapeutics, a spin-out of the University of Edinburgh, which is advancing next-generation precision therapeutics for fibrosis; and Signadori Bio, a novel cell therapy platform, developed from research at the Gustave Roussy Institute. 

Graziano Seghezzi, Managing Partner of Sofinnova Partners, said: “Building on the success of Biovelocita I in Italy, we have now developed a pan-European strategy and assembled a world class team to create and manage companies across the European biotech ecosystem. The strong response from our pharmaceutical partners and the fact that we exceeded our fundraising target underscore the demand for such an approach. This achievement highlights our commitment to fostering biotech innovation, supporting visionary entrepreneurs, and shaping the future of healthcare.” 

Led by Partners Gabriella Camboni, Matthieu Coutet, Alex Leech and Zhizhong Joel Yao, Sofinnova Biovelocita II stands as the largest Pan-European biotech accelerator. 

The Sofinnova Biovelocita strategy offers scientific founders a hands-on framework, combining direct management, financial support, and access to Sofinnova’s extensive infrastructure and network.

Diana Spencer, Senior Digital Content Editor, DDW